Caris Life Sciences, Inc. (NASDAQ:CAI – Get Free Report) insider Brian Brille sold 400,000 shares of Caris Life Sciences stock in a transaction on Thursday, September 17th. The stock was sold at an average price of $30.33, for a total transaction of $12,132,000.00. Following the sale, the insider directly owned 230,303 shares of the company’s stock, valued at $6,985,089.99. This represents a 63.46% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
Caris Life Sciences Stock Up 9.6%
CAI opened at $30.92 on Friday. The business’s fifty day simple moving average is $21.46 and its 200 day simple moving average is $19.26. Caris Life Sciences, Inc. has a 52 week low of $14.19 and a 52 week high of $34.54. The company has a quick ratio of 4.88, a current ratio of 5.53 and a debt-to-equity ratio of 0.66. The stock has a market cap of $8.74 billion, a PE ratio of 85.89 and a beta of 1.10.
Caris Life Sciences declared that its Board of Directors has approved a stock repurchase plan on Monday, June 8th that permits the company to buyback $100.00 million in outstanding shares. This buyback authorization permits the company to repurchase up to 2.1% of its stock through open market purchases. Stock buyback plans are generally a sign that the company’s management believes its shares are undervalued.
Analysts Set New Price Targets
Check Out Our Latest Report on Caris Life Sciences
Hedge Funds Weigh In On Caris Life Sciences
Large investors have recently bought and sold shares of the stock. PointState Capital LP bought a new stake in Caris Life Sciences during the 2nd quarter valued at $121,690,000. BlackRock Inc. bought a new stake in Caris Life Sciences in the 2nd quarter worth $98,666,000. Canada Pension Plan Investment Board bought a new stake in Caris Life Sciences in the 2nd quarter worth $24,502,000. Bank of America Corp DE purchased a new position in shares of Caris Life Sciences in the second quarter valued at about $21,395,000. Finally, Amundi raised its stake in shares of Caris Life Sciences by 5,709.5% during the second quarter. Amundi now owns 1,218,364 shares of the company’s stock valued at $21,711,000 after acquiring an additional 1,197,392 shares during the last quarter.
Caris Life Sciences Company Profile
Caris Life Sciences is a precision medicine and biotechnology company headquartered in Irving, Texas. Founded in 2008, the company combines molecular profiling, artificial intelligence and clinical data to support more informed decisions in cancer diagnosis and treatment.
Caris provides comprehensive tumor profiling and other laboratory testing services designed to identify genetic, molecular and immune characteristics of a patient’s cancer. Its offerings are intended to help physicians match patients with targeted therapies, immunotherapies and clinical trials, while also supporting cancer research and drug development.
The company serves healthcare providers, biopharmaceutical companies and academic or research institutions.
Featured Articles
- Five stocks we like better than Caris Life Sciences
- Aeluma’s Selloff Could Be Setting Up Its Next Big Move
- Crypto Bill Stalls, Smart Money Calls: Time to Buy the Dip?
- The September Scramble: Find Sanctuary in These 3 Defensive Dividend Stocks
- The Fed’s Rate Hike Could Backfire If Oil Prices Collapse
Receive News & Ratings for Caris Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caris Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
